register

News & Trends - Biotechnology

Agilex Biolabs acquires TetraQ for Asia Pacific expansion plans

Health Industry Hub | April 9, 2021 |

Biotech News: Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced the acquisition of leading biolab TetraQ, based at the University of Queensland. Agilex Biolabs CEO Jason Valentine said they were very pleased with the purchase of the high-calibre bioanalytics company.

“TetraQ complements the Agilex Biolabs work in Australia and APAC with its expert staff and years of experience in regulated bioanalytical services,” he said. “The TetraQ purchase is part of our regional expansion plans. Agilex Biolabs is already the largest and most technologically advanced biolab in Australia, and the TetraQ addition to the business will further expand support for biotech clients running trials in Australia.”

“We are also looking forward to introducing our clients to the well-established TetraQ toxicology capabilities for their discovery and pre-clinical work in Australia, which can also attract the 43.5% tax rebate. The clinical trials bioanalytics sector is one of the fastest-growing services globally with Australia and APAC a preferred location for conducting trials – especially since the COVID-19 pandemic.”

TetraQ Director Dr Peter Tapley said he was very pleased that TetraQ was now an Agilex Biolabs company. “They are the leader in the sector with 24 years of experience, and offer our clients a significantly expanded range of services and technologies,” he said.

“Agilex Biolabs is known globally for its comprehensive services, specialist scientists, and the very latest technology. So this is the ideal next step for TetraQ and its staff and clients. I am pleased to be working alongside Agilex Biolabs’ CEO Jason Valentine as we expand our offering and leverage the synergies that make our two companies leaders in the sector.”

Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarker and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gyrolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).

Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays.

Agilex Biolabs has 75 dedicated laboratory staff, and supports clinical research for biotech clients from US, Europe and APAC.


News & Trends - Pharmaceuticals

Clinical and Laboratory Haematologist and Lead of the Molecular Haematology Service

Clinicians call for closer monitoring of patients post CAR T therapy

Health Industry Hub | February 17, 2025 |

Australian clinicians are raising questions about whether cancer patients need closer monitoring after receiving CAR T-cell therapy. A Peter MacCallum […]

More


News & Trends - MedTech & Diagnostics

Next-gen surgical mesh to fill critical gap after ban

Next-gen surgical mesh to fill critical gap after regulatory ban

Health Industry Hub | February 17, 2025 |

Next-generation urogynaecological surgical mesh implants are on the horizon for women suffering from pelvic organ prolapse (POP). This development aims […]

More


News & Trends - Pharmaceuticals

Contraceptive lawsuit against Bayer fails

Contraceptive lawsuit against Bayer fails

Health Industry Hub | February 17, 2025 |

The Victorian Supreme Court has dismissed a class action against Bayer for an allegedly defective contraceptive device. Justice Andrew Keogh […]

More


News & Trends - Pharmaceuticals

NSW Government ignored warnings since 2018: Mental health system unravels as psychiatrists quit en masse

NSW Government ignored warnings since 2018: Mental health system unravels as psychiatrists quit en masse

Health Industry Hub | February 17, 2025 |

The New South Wales Labor government’s plan to “redesign” the state’s mental health system, while excluding psychiatrists, has sparked intense […]

More


This content is copyright protected. Please subscribe to gain access.